CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 1.6% during trading on Friday . The stock traded as low as $54.21 and last traded at $54.49. Approximately 299,571 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,642,465 shares. The stock had previously closed at $55.38.
Analysts Set New Price Targets
CRSP has been the topic of several research analyst reports. Oppenheimer dropped their price objective on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Needham & Company LLC reissued a “buy” rating and issued a $88.00 price objective on shares of CRISPR Therapeutics in a report on Thursday. Guggenheim restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Finally, Citigroup decreased their target price on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $75.71.
View Our Latest Research Report on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $25.53 million. The firm’s revenue was down 99.5% compared to the same quarter last year. During the same period last year, the business posted ($0.67) earnings per share. Research analysts anticipate that CRISPR Therapeutics AG will post -5.51 EPS for the current fiscal year.
Insider Activity
In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of CRSP. Blue Trust Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter worth $32,000. Bourgeon Capital Management LLC grew its stake in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares in the last quarter. Riggs Asset Managment Co. Inc. lifted its holdings in CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after buying an additional 200 shares during the last quarter. Principal Securities Inc. purchased a new stake in CRISPR Therapeutics during the 4th quarter worth about $41,000. Finally, NBC Securities Inc. lifted its holdings in CRISPR Therapeutics by 257.6% during the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after buying an additional 438 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More
- Five stocks we like better than CRISPR Therapeutics
- Investing in Commodities: What Are They? How to Invest in Them
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 6/24 – 6/28
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.